[1]
|
Noubiap, J.J., Nansseu, J.R., Nyaga, U.F., Sime, P.S., et al. (2019) Global Prevalence of Resistant Hypertension: A Meta-Analysis of Data from 3.2 Million Patients. Heart, 105, 98-105. https://doi.org/10.1136/heartjnl-2018-313599
|
[2]
|
Muntner, P., Davis, B.R., Cushman, W.C., Bangalore, S., et al. (2014) Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hyperten-sion, 64, 1012-1021.
https://doi.org/10.1161/HYPERTENSIONAHA.114.03850
|
[3]
|
Wang, Z., Chen, Z., Zhang, L., Wang, X., et al. (2018) Status of Hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation, 137, 2344-2356.
https://doi.org/10.1161/CIRCULATIONAHA.117.032380
|
[4]
|
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., et al. (2023) 2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension, 41, 1874-2071. https://doi.org/10.1097/HJH.0000000000003480
|
[5]
|
Cheung, A.K., Chang, T.I., Cushman, W.C., et al. (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney In-ternational, 99, S1-S87.
https://doi.org/10.1016/j.kint.2020.11.003
|
[6]
|
Bakris, G.L., Fonseca, V.A., Sharma, K. and Wright, E.M. (2009) Renal Sodium-Glucose Transport: Role in Diabetes Mellitus and Potential Clinical Implications. Kidney International, 75, 1272-1277.
https://doi.org/10.1038/ki.2009.87
|
[7]
|
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., et al. (2015) Empagli-flozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373, 2117-2128.
https://doi.org/10.1056/NEJMoa1504720
|
[8]
|
Neal, B., Perkovic, V., Mahaffey, K.W., De Zeeuw, D., et al. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377, 644-657.
https://doi.org/10.1056/NEJMoa1611925
|
[9]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380,347-357. https://doi.org/10.1056/NEJMoa1812389
|
[10]
|
Cannon, C.P., Pratley, R., Dagogo-Jack, S., Mancuso, J., et al. (2020) Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The New England Journal of Medicine, 383, 1425-1435.
https://doi.org/10.1056/NEJMoa2004967
|
[11]
|
Rosenstock, J., Marquard, J., Laffel, L.M., Neubacher, D., et al. (2018) Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 41, 2560-2569. https://doi.org/10.2337/dc18-1749
|
[12]
|
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., et al. (2018) Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 41, 2552-2559.
https://doi.org/10.2337/dc18-1087
|
[13]
|
Mathieu, C., Rudofsky, G., Phillip, M., Araki, E., et al. (2020) Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-Week Results from a Randomized Controlled Trial. Diabetes, Obesity & Metabolism, 22, 1516-1526. https://doi.org/10.1111/dom.14060
|
[14]
|
Mathieu, C., Dandona, P., Gillard, P., Senior, P., et al. (2018) Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 24-Week Re-sults from a Randomized Controlled Trial. Diabetes Care, 41, 1938-1946. https://doi.org/10.2337/dc18-0623
|
[15]
|
Buse, J.B., Garg, S.K., Rosenstock, J., Bailey, T.S., et al. (2018) Sotagli-flozin in Combination with Optimized Insulin Therapy in Adults with Type 1 Diabetes: The North American in Tandem1 Study. Diabetes Care, 41, 1970-1980.
https://doi.org/10.2337/dc18-0343
|
[16]
|
Garg, S.K., Henry, R.R., Banks, P., Buse, J.B., et al. (2017) Effects of So-tagliflozin Added to Insulin in Patients with Type 1 Diabetes. The New England Journal of Medicine, 377, 2337-2348.
https://doi.org/10.1056/NEJMoa1708337
|
[17]
|
Groop, P.H., Dandona, P., Phillip, M., Gillard, P., et al. (2020) Ef-fect of Dapagliflozin as an Adjunct to Insulin over 52 Weeks in Individuals with Type 1 Diabetes: Post-Hoc Renal Anal-ysis of the DEPICT Randomised Controlled Trials. The Lancet Diabetes & Endocrinology, 8, 845-854. https://doi.org/10.1016/S2213-8587(20)30280-1
|
[18]
|
Odutayo, A., Da Costa, B.R., Pereira, T.V., Garg, V., et al. (2021) Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression. Journal of the American Heart Association, 10, e019918. https://doi.org/10.1161/JAHA.120.019918
|
[19]
|
Muscoli, S., Barillà, F., Tajmir, R., Meloni, M., et al. (2022) The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics, 14, Article 1730.
https://doi.org/10.3390/pharmaceutics14081730
|
[20]
|
McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726.
https://doi.org/10.1093/eurheartj/ehab368
|
[21]
|
McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., et al. (2023) 2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 44, 3627-3639.
https://doi.org/10.1093/eurheartj/ehad195
|
[22]
|
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Køber, L., et al. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381, 1995-2008.
https://doi.org/10.1056/NEJMoa1911303
|
[23]
|
Packer, M., Anker, S.D., Butler, J., Filippatos, G., et al. (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine, 383, 1413-1424.
https://doi.org/10.1056/NEJMoa2022190
|
[24]
|
Anker, S.D., Butler, J., Filippatos, G., Ferreira, J.P., et al. (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385, 1451-1461. https://doi.org/10.1056/NEJMoa2107038
|
[25]
|
Li, M., Yi, T., Fan, F., Qiu, L., et al. (2022) Effect of Sodi-um-Glucose Cotransporter-2 Inhibitors on Blood Pressure in Patients with Heart Failure: A Systematic Review and Me-ta-Analysis. Cardiovascular Diabetology, 21, Article No. 139. https://doi.org/10.1186/s12933-022-01574-w
|
[26]
|
Baker, W.L., Buckley, L.F., Kelly, M.S., Bucheit, J.D., et al. (2017) Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 6, e005686. https://doi.org/10.1161/JAHA.117.005686
|
[27]
|
Obeid, A., Pucci, M., Martin, U. and Hanif, W. (2016) Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Resistant Hypertension: A Case Study. JRSM Open, 7. https://doi.org/10.1177/2054270416649285
|
[28]
|
Ferreira, J.P., Fitchett, D., Ofstad, A.P., Kraus, B.J., et al. (2020) Empagliflozin for Patients with Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. American Journal of Hypertension, 33, 1092-1101. https://doi.org/10.1093/ajh/hpaa073
|
[29]
|
Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
|
[30]
|
Pollock, C. and Neuen, B.L. (2021) Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People with and without Diabetes. Advances in Chronic Kidney Disease, 28, 298-308.
https://doi.org/10.1053/j.ackd.2021.02.006
|
[31]
|
Cherney, D.Z.I., Cooper, M.E., Tikkanen, I., Pfarr, E., et al. (2018) Pooled Analysis of Phase III Trials Indicate Contrasting Influences of Renal Function on Blood Pressure, Body Weight, and HbA1c Reductions with Empagliflozin. Kidney International, 93, 231-244. https://doi.org/10.1016/j.kint.2017.06.017
|
[32]
|
Ye, N., Jardine, M.J., Oshima, M., Hockham, C., et al. (2021) Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial. Circulation, 143, 1735-1749. https://doi.org/10.1161/CIRCULATIONAHA.120.048740
|
[33]
|
Bhatt, D.L., Szarek, M., Pitt, B., Cannon, C.P., et al. (2021) Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England Journal of Medicine, 384, 129-139. https://doi.org/10.1056/NEJMoa2030186
|
[34]
|
The EMPA-KIDNEY Collaborative Group, Her-rington, W.G., Staplin, N., Wanner, C., et al. (2023) Empagliflozin in Patients with Chronic Kidney Disease. New Eng-land Journal of Medicine, 388, 117-127.
https://doi.org/10.1056/NEJMoa2204233
|
[35]
|
Damman, K., Beusekamp, J.C., Boorsma, E.M., Swart, H.P., et al. (2020) Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clin-ical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF). European Journal of Heart Failure, 22, 713-722.
https://doi.org/10.1002/ejhf.1713
|
[36]
|
Griffin, M., Rao, V.S., Ivey-Miranda, J., Fleming, J., et al. (2020) Empagli-flozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation, 142, 1028-1039. https://doi.org/10.1161/CIRCULATIONAHA.120.045691
|
[37]
|
Mayne, KJ., Staplin, N., Keane, DF., Wanner, C., et al. (2023) Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease. J Am Soc Nephrol.
|
[38]
|
Wan, N., Fujisawa, Y., Kobara, H., Masaki, T., et al. (2020) Effects of an SGLT2 Inhibitor on the Salt Sensitivity of Blood Pressure and Sympathetic Nerve Activity in a Nondiabetic Rat Model of Chronic Kidney Dis-ease. Hypertension Research, 43, 492-499. https://doi.org/10.1038/s41440-020-0410-8
|
[39]
|
Kawasoe, S., Maru-guchi, Y., Kajiya, S., Uenomachi, H., et al. (2017) Mechanism of the Blood Pressure-Lowering Effect of Sodi-um-Glucose Cotransporter 2 Inhibitors in Obese Patientswith Type 2 Diabetes. BMC Pharmacology & Toxicology, 18, Article No. 23. https://doi.org/10.1186/s40360-017-0125-x
|
[40]
|
Scholtes, R.A., Muskiet, M.H.A., Van Baar, M.J.B., Hesp, A.C., et al. (2021) Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients with Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabe-tes Care, 44, 440-447. https://doi.org/10.2337/dc20-2604
|
[41]
|
Boorsma, E.M., Beusekamp, J.C., Ter Maaten, J.M., Figarska, S.M., et al. (2021) Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure. European Journal of Heart Failure, 23, 68-78.
https://doi.org/10.1002/ejhf.2066
|
[42]
|
Verma, S., McMurray, J.J.V. and Cherney, D.Z.I. (2017) The Metabolodi-uretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiology, 2, 939-940.
https://doi.org/10.1001/jamacardio.2017.1891
|
[43]
|
Xiao, L., Nie, X., Cheng, Y. and Wang, N. (2021) Sodi-um-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms. Cardiovascular Drugs and Therapy, 35, 1253-1267.
https://doi.org/10.1007/s10557-021-07216-9
|
[44]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., et al. (2018) The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. American Heart Journal, 200, 83-89.
https://doi.org/10.1016/j.ahj.2018.01.012
|
[45]
|
Lee, D.M., Battson, M.L., Jarrell, D.K., Hou, S., et al. (2018) SGLT2 Inhibition via Dapagliflozin Improves Generalized Vascular Dysfunction and Alters the Gut Microbiota in Type 2 Diabetic Mice. Cardiovascular Diabetology, 17, Article No. 62. https://doi.org/10.1186/s12933-018-0708-x
|
[46]
|
Madonna, R., Barachini, S., Moscato, S., Ippolito, C., et al. (2022) Sodium-Glucose Cotransporter Type 2 Inhibitors Prevent Ponatinib-Induced Endothelial Senescence and Disfunction: A Potential Rescue Strategy. Vascular Pharmacology, 142, Article ID: 106949. https://doi.org/10.1016/j.vph.2021.106949
|
[47]
|
Hong, J.Y., Park, K.Y., Kim, J.D., Hwang, W.M., et al. (2021) Response: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease. (J Obes Metab Syndr 2020; 29: 215-21). Journal of Obesity & Metabolic Syndrome, 30, 74-75. https://doi.org/10.7570/jomes21006
|
[48]
|
Van Bommel, E.J.M., Smits, M.M., Ruiter, D., Muskiet, M.H.A., et al. (2020) Effects of Dapagliflozin and Gliclazide on the Cardiorenal Axis in People with Type 2 Diabetes. Journal of Hypertension, 38, 1811-1819.
https://doi.org/10.1097/HJH.0000000000002480
|
[49]
|
Hidalgo Santiago, J.C., Maraver Delgado, J., Cayón Blanco, M., López Saez, J.B., et al. (2020) Effect of Dapagliflozin on Arterial Stiffness in Patients with Type 2 Diabetes Mellitus. Medicina Clinica, 154, 171-174.
https://doi.org/10.1016/j.medcli.2019.05.028
|
[50]
|
Papadopoulou, E., Loutradis, C., Tzatzagou, G., Kotsa, K., et al. (2021) Dapagliflozin Decreases Ambulatory Central Blood Pressure and Pulse Wave Velocity in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Hypertension, 39, 749-758. https://doi.org/10.1097/HJH.0000000000002690
|
[51]
|
Patoulias, D., Papadopoulos, C., Zografou, I., Katsimardou, A., et al. (2022) Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Dia-betes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study. Medicina, 58, Article 1167. https://doi.org/10.3390/medicina58091167
|
[52]
|
Wei, R., Wang, W., Pan, Q. and Guo, L, (2022) Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects with Type 2 Diabetes: A Systematic Re-view and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 13, Article 826604. https://doi.org/10.3389/fendo.2022.826604
|
[53]
|
Sawada, T., Uzu, K., Hashimoto, N., Onishi, T., et al. (2020) Em-pagliflozin;s Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 27, 644-656. https://doi.org/10.5551/jat.50807
|
[54]
|
Sposito, A.C., Breder, I., Soares, A.A.S., Kimura-Medorima, S.T., et al. (2021) Dapagliflozin Effect on Endothelial Dysfunction in Diabetic Patients with Atherosclerotic Disease: A Randomized Active-Controlled Trial. Cardiovascular Diabetology, 20, Article No. 74. https://doi.org/10.1186/s12933-021-01264-z
|
[55]
|
Juni, R.P., Al-Shama, R., Kuster, D.W.D., Van Der Velden, J., et al. (2021) Empagliflozin Restores Chronic Kidney Disease-Induced Impairment of Endothelial Regulation of Cardio-myocyte Relaxation and Contraction. Kidney International, 99, 1088-1101. https://doi.org/10.1016/j.kint.2020.12.013
|
[56]
|
Mancini, S.J., Boyd, D., Katwan, O.J., Strembitska, A., et al. (2018) Canagliflozin Inhibits Interleukin-1β-Stimulated Cytokine and Chemokine Secretion in Vascular Endothelial Cells by AMP-Activated Protein Kinase-Dependent and -Independent Mechanisms. Scientific Reports, 8, Article No. 5276. https://doi.org/10.1038/s41598-018-23420-4
|
[57]
|
Welborn, T.A., Breckenridge, A., Rubinstein, A.H., Dollery, C.T., et al. (1966) Serum-Insulin in Essential Hypertension and in Peripheral Vascular Disease. Lancet, 1, 1336-1337. https://doi.org/10.1016/S0140-6736(66)92132-5
|
[58]
|
Arnlöv, J., Pencina, M.J., Nam, B.H., Meigs, J.B., et al. (2005) Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking: Variations with Baseline Age, Body Mass Index, and Blood Pressure. Circulation, 112, 1719-1727.
https://doi.org/10.1161/CIRCULATIONAHA.105.535039
|
[59]
|
Joannides, C.N., Mangiafico, S.P., Waters, M.F., Lamont, B.J., et al. (2017) Dapagliflozin Improves Insulin Resistance and Glucose Intolerance in a Novel Transgenic Rat Model of Chronic Glucose Overproduction and Glucose Toxicity. Diabetes, Obesity & Metabolism, 19, 1135-1146. https://doi.org/10.1111/dom.12923
|
[60]
|
O;Brien, T.P., Jenkins, E.C., Estes, S.K., Castaneda, A.V., et al. (2017) Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats with An SGLT2 Inhibitor Restores Glucose Effec-tiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle. Diabetes, 66, 1172-1184. https://doi.org/10.2337/db16-1410
|
[61]
|
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., et al. (2014) Dapagliflozin Improves Muscle Insulin Sensitivity But Enhances Endogenous Glucose Production. The Journal of Clin-ical Investigation, 124, 509-514.
https://doi.org/10.1172/JCI70704
|
[62]
|
Jinnouchi, H., Yoshida, A., Tsuyuno, H., Iwamoto, K., et al. (2021) Changes in Urinary Glucose Concentration and Body Weight in Patients Treated with the Selective SGLT2 Inhibitor Luseogliflozin. Diabetes Research and Clinical Practice, 182, Article ID: 108916. https://doi.org/10.1016/j.diabres.2021.108916
|
[63]
|
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., et al. (2017) SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Re-sistance by Polarizing M2 Macrophages in Diet-Induced Obese Mice. eBioMedicine, 20,137-149. https://doi.org/10.1016/j.ebiom.2017.05.028
|
[64]
|
Okauchi, S., Shimoda, M., Obata, A., Kimura, T., et al. (2016) Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic β-Cells in Obese Type 2 Diabetic Db/Db Mice. Bio-chemical and Biophysical Research Communications, 470, 772-782. https://doi.org/10.1016/j.bbrc.2015.10.109
|
[65]
|
Hogan, M.F., Hackney, D.J., Aplin, A.C., Mundinger, T.O., et al. (2021) SGLT2-I Improves Markers of Islet Endothelial Cell Function in Db/Db Diabetic Mice. The Journal of Endocri-nology, 248, 95-106.
https://doi.org/10.1530/JOE-20-0354
|
[66]
|
Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., et al. (2015) Treatment with the SGLT2 Inhibitor Luseogliflozin Improves Nonalcoholic Steatohepatitis in a Rodent Model with Diabetes Melli-tus. Diabetology & Metabolic Syndrome, 7, Article No. 104. https://doi.org/10.1186/s13098-015-0102-8
|
[67]
|
Forman, J.P., Stampfer, M.J. and Curhan, G.C, (2009) Diet and Lifestyle Risk Factors Associated with Incident Hypertension in Women. JAMA, 302, 401-411. https://doi.org/10.1001/jama.2009.1060
|
[68]
|
Stamler, R., Stamler, J., Riedlinger, W.F., Algera, G., et al. (1978) Weight and Blood Pressure. Findings in Hypertension Screening of 1 Million Americans. JAMA, 240, 1607-1610.
https://doi.org/10.1001/jama.1978.03290150053024
|
[69]
|
Cai, X., Ji, L., Chen, Y., Yang, W., et al. (2017) Com-parisons of Weight Changes Between Sodium-Glucose Cotransporter 2 Inhibitors Treatment and Glucagon-Like Pep-tide-1 Analogs Treatment in Type 2 Diabetes Patients: A Meta-Analysis. Journal of Diabetes Investigation, 8, 510-517. https://doi.org/10.1111/jdi.12625
|
[70]
|
Lee, P.C., Ganguly, S. and Goh, S.Y. (2018) Weight Loss Associated with Sodium-Glucose Cotransporter-2 Inhibition: A Review of Evidence and Underlying Mechanisms. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 19, 1630-1641. https://doi.org/10.1111/obr.12755
|
[71]
|
Brown, R.E., Gupta, N. and Aronson, R, (2017) Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Diabetes Technology & Therapeutics, 19, 685-691. https://doi.org/10.1089/dia.2017.0134
|
[72]
|
Tandon, S., Ayis, S., Hopkins, D., Harding, S., et al. (2021) The Im-pact of Pharmacological and Lifestyle Interventions on Body Weight in People with Type 1 Diabetes: A Systematic Re-view and Meta-Analysis. Diabetes, Obesity & Metabolism, 23, 350-362. https://doi.org/10.1111/dom.14221
|
[73]
|
American Diabetes Association Professional Practice Committee (2022) 9 Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45, S125-S143.
https://doi.org/10.2337/dc22-S009
|
[74]
|
Wong, J., Chan, K.Y. and Lo, K. (2021) Sodium-Glucose Co-Transporter 2 Inhibitors on Weight Change and Cardiometabolic Profiles in Individuals with Overweight Or Obesity and without Diabetes: A Meta-Analysis. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 22, e13336.
https://doi.org/10.1111/obr.13336
|
[75]
|
Ohara, K., Masuda, T., Murakami, T., Imai, T., et al. (2019) Effects of the Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin on Fluid Distribution: A Comparison Study with Furosemide and Tolvaptan. Nephrology, 24, 904-911.
https://doi.org/10.1111/nep.13552
|
[76]
|
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., et al. (2016) Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects without Diabetes and Patients with Type 2 Diabetes. Diabetes, 65, 1190-1195. https://doi.org/10.2337/db15-1356
|
[77]
|
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., et al. (2017) Ipragliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Reduces Intrahepatic Lipid Content and Abdominal Visceral Fat Volume in Patients with Type 2 Diabetes. Expert Opinion on Pharmacotherapy, 18, 1433-1438. https://doi.org/10.1080/14656566.2017.1363888
|
[78]
|
Yamamoto, C., Miyoshi, H., Ono, K., Sugawara, H., et al. (2016) Ipragliflozin Effectively Reduced Visceral Fat in Japanese Patients with Type 2 Diabetes under Adequate Diet Therapy. Endocrine Journal, 63, 589-596.
https://doi.org/10.1507/endocrj.EJ15-0749
|
[79]
|
Xu, L. and Ota, T. (2018) Emerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on Fat Browning and Macrophage Polarization. Adipocyte, 7, 121-128. https://doi.org/10.1080/21623945.2017.1413516
|
[80]
|
Ost, A., Svensson, K., Ruishalme, I., Brännmark, C., et al. (2010) Attenuated MTOR Signaling and Enhanced Autophagy in Adipocytes from Obese Patients with Type 2 Diabetes. Molecular Medicine, 16, 235-246.
https://doi.org/10.2119/molmed.2010.00023
|
[81]
|
Costa, J., Moreira, A., Moreira, P., Delgado, L., et al. (2019) Ef-fects of Weight Changes in the Autonomic Nervous System: A Systematic Review and Meta-Analysis. Clinical Nutrition, 38, 110-126.
https://doi.org/10.1016/j.clnu.2018.01.006
|